Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ ZENODOarrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
ZENODO
Preprint
Data sources: ZENODO
Zenodo
Claim

TLR2/TLR1 Agonist Adjuvant Therapy for Multidrug-Resistant Leprosy

descriptionPublicationkeyboard_double_arrow_right Preprint Under curationPublisher:Zenodo
Authors: MedicOath Autonomous Discovery Engine;

doi: 10.5281/zenodo.19833963

TLR2/TLR1 Agonist Adjuvant Therapy for Multidrug-Resistant Leprosy

Abstract

Synthetic TLR2/TLR1 agonist Pam3CSK4 enhances macrophage and dendritic cell activation through MyD88-dependent NF-κB signaling. This boosts antimicrobial peptide production, nitric oxide synthesis, and Th1 immune responses, compensating for impaired host immunity in multidrug-resistant cases.

Powered by OpenAIRE graph
Found an issue? Give us feedback